 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial completion: A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - Dec 2, 2025
P2, N=448, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed
- || amycretin oral (NN9487 oral) / Novo Nordisk
P1 data, PK/PD data, Journal: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. (Pubmed Central) - Jul 12, 2025
P1
In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial completion: A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (clinicaltrials.gov) - May 23, 2025
P1, N=29, Completed, Sponsor: Novo Nordisk A/S
Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin. Recruiting --> Completed
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
Enrollment open: A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (clinicaltrials.gov) - Mar 11, 2025
P1, N=36, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Not yet recruiting --> Recruiting
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
New P1 trial: A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (clinicaltrials.gov) - Feb 11, 2025
P1, N=36, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| amycretin subcutaneous (NN9487 SC) / Novo Nordisk
Trial completion: A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - Jan 8, 2025
P2, N=125, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| zenagamtide oral (NN9487 oral) / Novo Nordisk
Enrollment open: A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - Aug 12, 2024
P2, N=432, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| zenagamtide oral (NN9487 oral) / Novo Nordisk
New P2 trial: A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - Aug 6, 2024
P2, N=432, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| amycretin subcutaneous (NN9487 SC) / Novo Nordisk
Phase classification, Enrollment change: A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - Jun 24, 2024
P2, N=120, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Phase classification: P1 --> P2 | N=84 --> 120
- | amycretin subcutaneous (NN9487 SC) / Novo Nordisk
Phase classification: A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - Mar 12, 2024
P1, N=84, Recruiting, Sponsor: Novo Nordisk A/S
Phase classification: P1 --> P2 | N=84 --> 120 Phase classification: P1/2 --> P1
- ||| zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial completion: A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - Jan 31, 2024
P1, N=144, Completed, Sponsor: Novo Nordisk A/S
Phase classification: P1/2 --> P1 Recruiting --> Completed
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial completion, Enrollment change: A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - Dec 21, 2023
P1, N=36, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Active, not recruiting --> Completed | N=120 --> 36
- | amycretin subcutaneous (NN9487 SC) / Novo Nordisk
Phase classification: A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - Dec 15, 2023
P1/2, N=84, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=120 --> 36 Phase classification: P1 --> P1/2
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
Enrollment closed: A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - Nov 27, 2023
P1, N=120, Active, not recruiting, Sponsor: Novo Nordisk A/S
Phase classification: P1 --> P1/2 Recruiting --> Active, not recruiting
- || zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial primary completion date: A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - Oct 6, 2023
P1, N=116, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2023 --> Jan 2024
- |||| amycretin subcutaneous (NN9487 SC) / Novo Nordisk
New P1 trial, New P1/2 trial: A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - Oct 3, 2023
P1, N=84, Recruiting, Sponsor: Novo Nordisk A/S
- ||| zenagamtide oral (NN9487 oral) / Novo Nordisk
New P1 trial: A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - Sep 22, 2023
P1, N=120, Recruiting, Sponsor: Novo Nordisk A/S
- | zenagamtide oral (NN9487 oral) / Novo Nordisk
Trial completion date: A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - Aug 9, 2023
P1, N=116, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2023 --> Jan 2024 Trial completion date: Jul 2023 --> Nov 2023
- ||| zenagamtide oral (NN9487 oral) / Novo Nordisk
Enrollment open: A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - May 24, 2022
P1, N=116, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Jul 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- ||| zenagamtide oral (NN9487 oral) / Novo Nordisk
New P1 trial: A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - May 11, 2022
P1, N=116, Not yet recruiting, Sponsor: Novo Nordisk A/S